Emily B Devine1, Alan W Hopefl, Ann K Wittkowsky. 1. Pharmaceutical Outcomes Research and Policy Program, University of Washington, Box 357630, Seattle, WA 98195-7630, USA. bdevine@u.washington.edu
Abstract
OBJECTIVES: The American College of Chest Physicians (ACCP) provides guidelines for the management of excessive anticoagulation in patients receiving warfarin. This multi-site prospective cohort study evaluated patient-level practice patterns and adherence to ACCP guidelines. METHODS: Patients presenting with an INR > or = 4.5 between January 3 and April 29, 2005 were observed and therapeutic management documented. Adherence was assessed retrospectively. RESULTS: Four hundred and seventeen patients from 22 centers were observed. The mean, initial INR was 7.7. At enrollment, 85% of the patients had an INR < 9 or were not bleeding; 15% were seriously bleeding. Treatment for 170 patients (41%) did not adhere to guidelines. Among those, 15% were undertreated, 48% overtreated. Lack of adherence was attributed primarily to excessive doses (mean initial dose = 6.9 mg) and inappropriate routes of administration (subcutaneous or intramuscular) of vitamin K1. CONCLUSION: Adherence to the ACCP guidelines is low. Inappropriate use of vitamin K1 is the primary reason.
OBJECTIVES: The American College of Chest Physicians (ACCP) provides guidelines for the management of excessive anticoagulation in patients receiving warfarin. This multi-site prospective cohort study evaluated patient-level practice patterns and adherence to ACCP guidelines. METHODS:Patients presenting with an INR > or = 4.5 between January 3 and April 29, 2005 were observed and therapeutic management documented. Adherence was assessed retrospectively. RESULTS: Four hundred and seventeen patients from 22 centers were observed. The mean, initial INR was 7.7. At enrollment, 85% of the patients had an INR < 9 or were not bleeding; 15% were seriously bleeding. Treatment for 170 patients (41%) did not adhere to guidelines. Among those, 15% were undertreated, 48% overtreated. Lack of adherence was attributed primarily to excessive doses (mean initial dose = 6.9 mg) and inappropriate routes of administration (subcutaneous or intramuscular) of vitamin K1. CONCLUSION: Adherence to the ACCP guidelines is low. Inappropriate use of vitamin K1 is the primary reason.
Authors: G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi Journal: Lancet Date: 1996-08-17 Impact factor: 79.321
Authors: M A Crowther; J Julian; D McCarty; J Douketis; M Kovacs; L Biagoni; T Schnurr; J McGinnis; M Gent; J Hirsh; J Ginsberg Journal: Lancet Date: 2000-11-04 Impact factor: 79.321
Authors: Daniel E Singer; Gregory W Albers; James E Dalen; Alan S Go; Jonathan L Halperin; Warren J Manning Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: Robert A Harrington; Richard C Becker; Michael Ezekowitz; Thomas W Meade; Christopher M O'Connor; David A Vorchheimer; Gordon H Guyatt Journal: Chest Date: 2004-09 Impact factor: 9.410